167683-92-3

Usage

Structure

A benzene ring with a chlorine atom at position 1, an ethoxy group at position 4, a fluorine atom at position 3, and a vinyl group at position 2.

Derivative

It is a derivative of benzene.

Usage

Used in organic synthesis with applications in pharmaceutical and agrochemical industries.

Physical state

A colorless liquid.

Odor

Strong odor.

Safety precautions

Can be harmful if ingested, inhaled, or comes into contact with skin or eyes.

Environmental risks

May pose environmental risks and should be properly handled and disposed of according to regulations.

Upstream product

• 1779-49-3 Methyltriphenylphosphonium bromide 
• 289039-40-3 4-chloro-1-ethoxy-2-fluoro-benzene 
• 363620-21-7 6-chloro-3-ethoxy-2-fluoro-benzaldehyde 
• 348-62-9 4-chloro-2-fluorophenol 

Downstream Products

• 417709-92-3 (1S,2R)-cis-2-(6-chloro-3-ethoxy-2-fluorophenyl)cyclopropanecarboxylic acid 
• 417709-90-1 tert-butyl (1S,2R)-cis-2-(6-chloro-3-ethoxy-2-fluorophenyl)-cyclopropanecarboxylate 
• 417709-89-8 ethyl (1S,2R)-cis-2-(6-chloro-3-ethoxy-2-fluorophenyl)-cyclopropanecarboxylate 

Relevant academic research and scientific papers

In search of high stereocontrol for the construction of cis-disubstituted cyclopropane compounds. Total synthesis of a cyclopropane-configured urea-PETT analogue that is a HIV-1 reverse transcriptase inhibitor.

[reaction: see text] A new azetidine-ligated dirhodium(II) catalyst that possesses a l-menthyl ester attachment provides significant diastereocontrol and high enantiocontrol for the formation of cis-cyclopropane products from reactions of substituted styr

Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues

The further development of allosteric HIV-1 RT inhibitors in the urea analogue series of PETT (phenylethylthiazolylthiourea) derivatives is described here. The series includes derivatives with an ethyl linker (1-5) and racemic (6-16) and enantiomeric (17-

N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection

A method for treating HIV which comprises a compound of the formula STR1 wherein A is STR2 and Zi is O, Se, NRa or C(Ra)2, and Zii is --O or (=O)2 ; wherein R1, R2, R3, and R4 are as defined in the specification.